U.S. approves new booster of COVID-19 vaccines, “mix and match” dose

The U.S. Food and Drug Administration (FDA) on Wednesday authorized COVID-19 booster doses of Moderna and Johnson & Johnson, and approved “mix and match” booster dose for currently available approved COVID-19 vaccines.

The agency authorized the use of a single booster dose of the Moderna COVID-19 vaccine at least 6 months after completion of the primary shots to people 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

As for the Johnson & Johnson booster dose, the FDA authorized the use of a single booster dose at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.

A single booster dose of any of the available COVID-19 vaccines may be administered as a “mix and match” booster dose following completion of primary vaccination with a different available COVID-19 vaccine, according to the FDA.

For instance, a person who got a Johnson & Johnson vaccine could receive one from Moderna or Pfizer-BioNTech as a booster.

“The available data suggest waning immunity in some populations who are fully vaccinated,” said Acting FDA Commissioner Janet Woodcock in a statement. “The availability of these authorized boosters is important for continued protection against COVID-19 disease.”

The decision came after an FDA advisory committee voted last week to recommend authorizing Moderna and Johnson & Johnson’s COVID-19 booster doses.

In September, the FDA authorized the first booster shots for the Pfizer-BioNTech COVID-19 vaccine, allowing a single booster dose of the Pfizer-BioNTech vaccine be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

A recent study of the “mix and match” approach funded by the U.S. National Institutes of Health found no safety concerns using different vaccines as a booster.

The study found that people who received the Johnson & Johnson vaccine produced stronger antibody levels after they got booster shots made by Moderna or Pfizer-BioNTech, compared to boosters from Johnson & Johnson. -rir

Popular

Palace: PBBM admin remains firm on stance against corruption

By Dean Aubrey Caratiquet Malacañang reaffirmed the administration’s sincere intentions as it makes strides in stemming various forms of corruption at the grassroots level. This, in...

DSWD: Mindanao disaster resource hub construction to begin soon

By Joyce Ann L. Rocamora | Philippine News Agency The construction of the first Mindanao disaster resource hub will soon begin, the Department of Social...

D.A., DOT to lead PH participation in Green Expo 2027 in Japan

By Brian Campued The Department of Agriculture (DA) and Department of Tourism (DOT) were tapped to lead the Philippines’ preparations and participation at the Green...

ICI submits 125-day report to Palace

The Independent Commission for Infrastructure (ICI) on Friday submitted to Malacañang its 125-day accomplishment report covering the period from Sept. 15 last year to...